FDA Approves Annovera

NEW YORK, Aug. 10, 2018 /PRNewswire/ — The Population Council, a global nonprofit research organization, announced it has received U.S. Food and Drug Administration (FDA) approval for Annovera™ (segesterone acetate and ethinyl estradiol vaginal system), the first and only contraceptive that provides an entire year of protection against unintended pregnancy while fully under a woman’s control. The approval marks an […]

Read more

Benzodiazepine and related drug prescriptions have increased among young people in Sweden

The prevalence rate of prescriptions for benzodiazepines and benzodiazepine-related drugs (BZD)—medications used to treat anxiety, insomnia, epilepsy and other neuropsychiatric conditions—increased by 22% between 2006 and 2013 among individuals aged 0-24 years in Sweden, according to a study published this week in PLOS Medicine. The study, conducted by Anna Sidorchuk of the Karolinska Institutet, Stockholm, and colleagues, indicates that during […]

Read more

United Therapeutics Announces FDA Approval of the Implantable System for Remodulin

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., July 31, 2018 /PRNewswire/ — United Therapeutics Corporation (NASDAQ: UTHR) today announced approval by the U.S. Food and Drug Administration (FDA) of a New Drug Application (NDA) for the use of Remodulin (treprostinil) Injection in the Implantable System for Remodulin® (ISR). The ISR has been developed under a collaboration with Medtronic (NYSE: […]

Read more

Here’s Why Your Pharmacist Won’t Fill Your Prescription — and What You Can Do About It (Part 1)

This is Part 1 in our two-part series on why pharmacists may not fill your prescription. In Part 2, we cover issues like scripts that looked altered and possible drug-drug interactions.  Here are four reasons why your pharmacist can refuse to fill your prescription: 1) The prescription is missing information. Pharmacies receive prescriptions in a couple of different ways: Prescriptions […]

Read more

Behavioral nudges lead to striking drop in prescriptions of potent antipsychotic

A study led by Columbia University’s Mailman School of Public Health has found that letters targeting high prescribers of Seroquel (quetiapine), an antipsychotic with potentially harmful side effects in the elderly, significantly reduced the number of prescriptions for patients in Medicare. The results showed that peer comparison letters led to statistically meaningful, persistent decreases in quetiapine prescribing, with no detected […]

Read more

Maryland hits record-high drug deaths, fueled by fentanyl

Maryland notched a record-high number of drug deaths last year, fueled by an alarming increase of fentanyl-related fatalities amid an escalating epidemic. Newly released figures from Maryland’s health department show there were 2,282 intoxication deaths in 2017. Nearly 90 percent of those deaths were opioid-related. The hard-hit state’s fentanyl-related deaths continue to soar, increasing from 1,119 in 2016 to an […]

Read more

Judge: Opioid distribution data not for public consumption

A federal judge has ruled that state and local governments cannot publicize federal government data about where prescription opioids were distributed—a blow to news organizations seeking to report more deeply on the nation’s overdose and addiction crisis. The U.S. Drug Enforcement Agency is providing the information to state and local governments to use in their lawsuits against companies that make, […]

Read more

New Low Prices With Walmart’s Prescription Savings Program

With the Walmart Rx Program, you can get select generic medications at $4 for a 30-day supply and $10 for a 90-day supply. It doesn’t require a membership, and these low cash prices are available with or without insurance. All you need to do is take your prescription to a Walmart pharmacy counter and speak with your pharmacist about their […]

Read more

FDA Approves Orilissa

NORTH CHICAGO, Ill., July 24, 2018 /PRNewswire/ — AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), announced that the U.S. Food and Drug Administration (FDA) approved Orilissa (elagolix), the first and only oral gonadotropin-releasing hormone (GnRH) antagonist specifically developed for women with moderate to severe endometriosis pain.1,2 The FDA approved Orilissa under […]

Read more

Pfizer And Lilly Announce Positive Top-Line Results From Phase 3 Trial Of Tanezumab For The Treatment Of Osteoarthritis (OA) Pain

July 18, 2018 – Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced that a 16-week Phase 3 study in patients with osteoarthritis (OA) pain evaluating subcutaneous administration of tanezumab, an investigational humanized monoclonal antibody, met all three co-primary endpoints. The study demonstrated that patients who received two doses of tanezumab separated by eight weeks experienced a statistically […]

Read more
1 20 21 22 23